Treatment of Early Breast Cancer: A Foreseeable Future for Adjuvant Therapy

Clinton Yam, MD


August 01, 2022

Clinton Yam, MD, offers a recollection from residency in which a patient with early triple-negative breast cancer (TNBC) developed treatment resistance at the time of surgery. In the absence of any approved adjuvant treatments at that time, active surveillance was the patient's recourse. When recurrent cancer was subsequently detected, new rounds of chemotherapy failed to halt the course of the disease.

The corollary of this experience, Dr Yam suggests, is the need for effective adjuvant therapies for early breast cancers, including PARP inhibitors, CDK4/6 inhibitors with endocrine therapy, and antibody-drug conjugates, so that disease recurrence can be minimized and patient outcomes improved.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.